Stock Analysis

Need To Know: The Consensus Just Cut Its Merus N.V. (NASDAQ:MRUS) Estimates For 2025

Today is shaping up negative for Merus N.V. (NASDAQ:MRUS) shareholders, with the analysts delivering a substantial negative revision to this year's forecasts. There was a fairly draconian cut to their revenue estimates, perhaps an implicit admission that previous forecasts were much too optimistic.

After this downgrade, Merus' 17 analysts are now forecasting revenues of US$39m in 2025. This would be a modest 6.7% improvement in sales compared to the last 12 months. Losses are supposed to balloon 33% to US$4.14 per share. Yet before this consensus update, the analysts had been forecasting revenues of US$49m and losses of US$3.97 per share in 2025. So there's been quite a change-up of views after the recent consensus updates, with the analysts making a serious cut to their revenue forecasts while also expecting losses per share to increase.

View our latest analysis for Merus

earnings-and-revenue-growth
NasdaqGM:MRUS Earnings and Revenue Growth March 5th 2025

There was no major change to the consensus price target of US$86.56, signalling that the business is performing roughly in line with expectations, despite lower earnings per share forecasts.

These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Merus' past performance and to peers in the same industry. The analysts are definitely expecting Merus' growth to accelerate, with the forecast 6.7% annualised growth to the end of 2025 ranking favourably alongside historical growth of 5.0% per annum over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 20% per year. So it's clear that despite the acceleration in growth, Merus is expected to grow meaningfully slower than the industry average.

Advertisement

The Bottom Line

The most important thing to note from this downgrade is that the consensus increased its forecast losses this year, suggesting all may not be well at Merus. Regrettably, they also downgraded their revenue estimates, and the latest forecasts imply the business will grow sales slower than the wider market. Overall, given the drastic downgrade to this year's forecasts, we'd be feeling a little more wary of Merus going forwards.

Even so, the longer term trajectory of the business is much more important for the value creation of shareholders. At Simply Wall St, we have a full range of analyst estimates for Merus going out to 2027, and you can see them free on our platform here.

Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are downgrading their estimates. So you may also wish to search this free list of stocks with high insider ownership.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

β€’ Connect an unlimited number of Portfolios and see your total in one currency
β€’ Be alerted to new Warning Signs or Risks via email or mobile
β€’ Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About NasdaqGM:MRUS

Merus

A clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands.

Flawless balance sheet and fair value.

Advertisement

Weekly Picks

AL
RKLB logo
AlexLovell on Rocket Lab Β·

Early mover in a fast growing industry. Likely to experience share price volatility as they scale

Fair Value:US$16.25367.6% overvalued
68 users have followed this narrative
1 users have commented on this narrative
18 users have liked this narrative
AG
Agricola
EXN logo
Agricola on Excellon Resources Β·

A case for CA$31.80 (undiluted), aka 8,616% upside from CA$0.37 (an 86 bagger!).

Fair Value:CA$31.898.3% undervalued
66 users have followed this narrative
10 users have commented on this narrative
19 users have liked this narrative
FU
FundamentallySarcastic
CCP logo
FundamentallySarcastic on Credit Corp Group Β·

Moderation and Stabilisation: HOLD: Fair Price based on a 4-year Cycle is $12.08

Fair Value:AU$12.6410.4% overvalued
11 users have followed this narrative
1 users have commented on this narrative
0 users have liked this narrative

Updated Narratives

YI
XRAY logo
yiannisz on DENTSPLY SIRONA Β·

Dentsply Sirona Stock: Dental Technology Built for Cycles, Not Headlines

Fair Value:US$45.575.2% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
YI
ETSY logo
yiannisz on Etsy Β·

Etsy Stock: Defending Differentiation in a World of Infinite Marketplaces

Fair Value:US$64.4511.1% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
YI
ALGN logo
yiannisz on Align Technology Β·

Align Technology Stock: Premium Orthodontics in a Cost-Sensitive World

Fair Value:US$154.620.9% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

AG
Agricola
EXN logo
Agricola on Excellon Resources Β·

A case for CA$31.80 (undiluted), aka 8,616% upside from CA$0.37 (an 86 bagger!).

Fair Value:CA$31.898.3% undervalued
66 users have followed this narrative
10 users have commented on this narrative
19 users have liked this narrative
AL
RKLB logo
AlexLovell on Rocket Lab Β·

Early mover in a fast growing industry. Likely to experience share price volatility as they scale

Fair Value:US$16.25367.6% overvalued
68 users have followed this narrative
1 users have commented on this narrative
18 users have liked this narrative
AN
AnalystConsensusTarget
NVDA logo
AnalystConsensusTarget on NVIDIA Β·

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026

Fair Value:US$253.0225.4% undervalued
1014 users have followed this narrative
6 users have commented on this narrative
28 users have liked this narrative